Imprida Unjoni Ewropea - Malti - EMA (European Medicines Agency)

imprida

novartis europharm ltd - valsartan, amlodipine (as amlodipine besilate) - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali. imprida huwa indikat f'pazjenti li l-pressjoni tad-demm mhijiex ikkontrollata adegwatament bl-amlodipina jew valsartan monoterapija.

Targretin Unjoni Ewropea - Malti - EMA (European Medicines Agency)

targretin

eisai gmbh - bexarotene - limfoma, t-Ċellula, kutanja - aġenti antineoplastiċi - il-kapsuli ta 'targretin huma indikati għall-kura ta' manifestazzjonijiet tal-ġilda ta 'pazjenti b'liprofoma t taċ-ċelluli t tal-palulu avvanzati (ctcl) refrattorji għal mill-inqas trattament wieħed sistemiku.

Prasugrel Mylan Unjoni Ewropea - Malti - EMA (European Medicines Agency)

prasugrel mylan

mylan pharmaceuticals limited - prasugrel besilate - myocardial infarction; acute coronary syndrome; angina, unstable - aġenti antitrombotiċi - prasugrel mylan, ko-amministrat ma ' acetylsalicylic acid (asa), huwa indikat għall-prevenzjoni ta'avvenimenti aterotrombotiċi f'pazjenti adulti b'sindromu koronarju akut (i. anġina instabbli, mhux tas-segment st 'infart mijokardijaku b'elevazzjoni [ua/nstemi] jew elevazzjoni tas-segment st' infart mijokardijaku [stemi]) li għaddejjin minn primarju jew ittardjat ta ' intervent koronarju perkutaneju (pci).

Mycapssa Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mycapssa

amryt pharmaceuticals dac - octreotide acetate - acromegaly - ormoni u analogi pitwitarji u ipotalamiċi - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

Cyanokit Unjoni Ewropea - Malti - EMA (European Medicines Agency)

cyanokit

serb sa - hydroxocobalamin - avvelenament - il-prodotti terapewtiċi l-oħra kollha - trattament ta 'avvelenament magħruf jew suspettat ta' cyanide. cyanokit għandu jingħata flimkien ma adegwati ta ' dekontaminazzjoni u miżuri ta'appoġġ.

Verquvo Unjoni Ewropea - Malti - EMA (European Medicines Agency)

verquvo

bayer ag - vericiguat - insuffiċjenza tal-qalb - terapija kardijaka - treatment of symptomatic chronic heart failure.

BiResp Spiromax Unjoni Ewropea - Malti - EMA (European Medicines Agency)

biresp spiromax

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

DuoResp Spiromax Unjoni Ewropea - Malti - EMA (European Medicines Agency)

duoresp spiromax

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Enzepi Unjoni Ewropea - Malti - EMA (European Medicines Agency)

enzepi

allergan pharmaceuticals international ltd - trab tal-frixa - insuffiċjenza pankreatika exocrine - diġestivi, inkl. enżimi - trattament ta 'sostituzzjoni ta' enzimi pankreatiċi f'insuffiċjenza pankreatika exocrine minħabba fibrożi ċistika jew kundizzjonijiet oħra (e. pankreatite kronika, pankreatectomija ta 'wara jew kanċer tal-frixa). enzepi huwa indikat fit-trabi, tfal, l-adoloxxenti u l-adulti.

Novaquin Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novaquin

le vet beheer b.v.  - meloxicam - oxicams - Żwiemel - tnaqqis ta 'infjammazzjoni u eżenzjoni ta' uġigħ kemm f'mard muskolu-skeletriku akut kif ukoll kroniku fiż-żwiemel.